AVNS — Avanos Medical, Inc.

Avanos Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year Net Sales: $701 million, exceeding revised guidance.
• Adjusted Diluted EPS: $0.94 for the full year; $0.29 for Q4.
• Adjusted EBITDA: $87 million for the year; $28 million for Q4.
• Adjusted Gross Margin: 54.6% for the year; 53.4% for Q4.
• SG&A as a Percentage of Revenue: 42% for the year; 39.1% for Q4.
• Free Cash Flow: $43 million for the year; $21 million for Q4.
• Cash Position: $90 million in cash with $100 million in debt.

2. Strategic Updates and Business Highlights

• Specialty Nutrition Systems (SNS): Grew over 8% organically, driven by strong demand for long-term and short-term enteral feeding products.
• Pain Management and Recovery (PM&R): Normalized organic sales up 2.3%, with notable growth in radiofrequency ablation (RFA) products.
• Tariff Mitigation: Initiatives in place to address tariff impacts, including cost containment and pricing strategies. Expect benefits from these measures in 2026.
• Portfolio Management: Completed divestitures of hyaluronic acid and IV therapy businesses, and acquired Nexus Medical, which is performing better than expected.
• Operational Efficiencies: Ongoing efforts to improve cost structure and manage underperforming assets.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected net sales between $700 million and $720 million, with mid- to high single-digit growth in SNS and low to mid-single-digit growth in PM&R.
• Adjusted EPS Guidance: Projected between $0.90 and $1.10, factoring in $30 million in tariff-related costs.
• Capital Expenditures: Anticipated at $25 million, supporting the exit from China for syringe production by June 2026.
• Gross Margin Expectations: Anticipated pause in gross margin improvement in the first half of 2026 due to tariffs, with recovery expected in the second half.

4. Bad News, Challenges, or Points of Concern

• Tariff Impact: Continued unfavorable tariff expenses, projected to increase by $12 million in 2026 compared to 2025.
• Surgical Pain Business: Year-over-year decline attributed to slower-than-expected implementation of the NOPAIN Act.
• GAME READY Portfolio: Revenue levels remained flat year-over-year, indicating challenges in this segment.
• Market and Regulatory Risks: Ongoing evaluation of tariff negotiations and potential impacts from recent Supreme Court rulings.

5. Notable Q&A Insights

• Tariff Strategy: Management expressed confidence in mitigating tariff impacts through various strategies, including exiting China for syringe production by mid-2026.
• Organic Growth Projections: Consolidated organic growth expected around 5%, with specific segment growth rates provided.
• Operating Leverage: Management indicated confidence in maintaining operating efficiencies and cost management, despite increased tariff expenses.
• Nexus Acquisition Performance: Early results from the Nexus acquisition exceeded expectations, with projected double-digit growth for 2026.

Overall, Avanos reported solid financial performance in 2025, driven by strategic initiatives in its Specialty Nutrition Systems segment, while navigating challenges related to tariffs and certain product lines. The company is optimistic about its growth trajectory heading into 2026, despite facing some headwinds.